BEVACIZUMAB

Brand name:

• Abevmy®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Alphapharm Pty Ltd

Condition/indication:
(therapeutic use)

• Relapsed or recurrent glioblastoma; Advanced (unresectable) Barcelona Clinic Liver Cancer; Stage B or Stage C hepatocellular carcinoma; Stage IV (metastatic) non-small cell lung cancer (NSCLC); Advanced carcinoma of cervix; Advanced International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB, IIIC or Stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer; Metastatic colorectal cancer.

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (–)

Comment:

--

Other PBAC consideration:

--

Submission received for:

November 2021 PBAC meeting

Opportunity for consumer comment:

Open 28/07/2021 and close 22/09/2021 (see PBS Website)

PBAC meeting:

Held on 03/11/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

21/08/2022

Lodgement of required documentation:

31/08/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 08/09/2022

Status:

Finalised

Government processes:

Commenced on 19/10/2022

Medicine listed on the PBS:

01/12/2022 (see PBS schedule)